Sivik Global Healthcare LLC lifted its position in shares of TESARO, Inc. (NASDAQ:TSRO) by 42.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,000 shares of the biopharmaceutical company’s stock after acquiring an additional 4,500 shares during the period. Sivik Global Healthcare LLC’s holdings in TESARO were worth $2,098,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the stock. FMR LLC raised its position in shares of TESARO by 0.4% during the 1st quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock valued at $1,237,718,000 after acquiring an additional 32,918 shares in the last quarter. BlackRock Inc. raised its position in shares of TESARO by 5.7% during the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after acquiring an additional 195,590 shares in the last quarter. Vanguard Group Inc. raised its position in shares of TESARO by 3.7% during the 1st quarter. Vanguard Group Inc. now owns 2,916,132 shares of the biopharmaceutical company’s stock valued at $448,705,000 after acquiring an additional 103,759 shares in the last quarter. State Street Corp raised its position in shares of TESARO by 0.4% during the 1st quarter. State Street Corp now owns 991,856 shares of the biopharmaceutical company’s stock valued at $152,617,000 after acquiring an additional 3,784 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of TESARO by 4.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 703,774 shares of the biopharmaceutical company’s stock valued at $98,430,000 after acquiring an additional 28,177 shares in the last quarter.
TESARO, Inc. (NASDAQ:TSRO) traded up 1.67% on Friday, hitting $117.16. The stock had a trading volume of 1,253,722 shares. The firm’s 50-day moving average price is $121.74 and its 200-day moving average price is $140.42. The firm’s market cap is $6.35 billion. TESARO, Inc. has a 1-year low of $96.52 and a 1-year high of $192.94.
TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). The company had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. TESARO’s quarterly revenue was down 17.6% compared to the same quarter last year. During the same quarter last year, the business earned ($1.28) EPS. On average, equities research analysts predict that TESARO, Inc. will post ($8.67) earnings per share for the current year.
In other TESARO news, VP Edward C. English sold 10,862 shares of TESARO stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total value of $1,465,501.04. Following the completion of the transaction, the vice president now owns 6,258 shares in the company, valued at approximately $844,329.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,100 shares of company stock valued at $3,387,465. Corporate insiders own 40.50% of the company’s stock.
TSRO has been the topic of several research reports. Gabelli initiated coverage on TESARO in a research report on Friday, July 7th. They set a “buy” rating and a $175.00 price target on the stock. ValuEngine raised TESARO from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Oppenheimer Holdings, Inc. initiated coverage on TESARO in a research report on Thursday, May 25th. They set an “outperform” rating and a $183.00 price target on the stock. Wedbush raised TESARO to an “outperform” rating and set a $168.00 price target on the stock in a research report on Monday, June 5th. Finally, Credit Suisse Group set a $198.00 price target on TESARO and gave the company a “buy” rating in a research report on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $171.42.
ILLEGAL ACTIVITY WARNING: “Sivik Global Healthcare LLC Boosts Position in TESARO, Inc. (TSRO)” was reported by Equities Focus and is the property of of Equities Focus. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.equitiesfocus.com/2017/09/17/sivik-global-healthcare-llc-boosts-position-in-tesaro-inc-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO, Inc. (NASDAQ:TSRO).
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.